SCHEMBL1750239

SCHEMBL1750239

O=C1CCC2(CC1)CCN(Cc1c(Cl)cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)cc1Cl)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 5/20 0.46
HDAC11 Q96DB2 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
PDE5A O76074 1/20 0.37
PDE4A P27815 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE7A Q13946 1/20 0.37
PDE1C Q14123 1/20 0.37
PDE3A Q14432 1/20 0.37
PDE7B Q9NP56 1/20 0.37
FASN P49327 4/20 0.35
USP7 Q93009 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.34
HTR1A P08908 2/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750369 0.91 RIPK1 (0.46) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750051 0.91 RIPK1 (0.46) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750368 0.91 RIPK1 (0.46) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750671 0.87 RIPK1 (0.41) RIPK1HDAC11HDAC6PDE5APDE4A
SCHEMBL1752110 0.79 RIPK1 (0.42) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL3033937 0.79 RIPK1 (0.42) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750077 0.79 PDE7B (0.45) RIPK1PDE5APDE4APDE1APDE1B
SCHEMBL3045877 0.79 RIPK1 (0.42) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750125 0.78 RIPK1 (0.41) RIPK1HDAC11PDE5APDE4APDE1A
SCHEMBL1750321 0.76 PDE5A (0.47) RIPK1HDAC11HDAC6PDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968585-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-06-28 US disclosed
EP-2035379-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-16 EP disclosed
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2035379-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-18 EP disclosed
WO-2007127763-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 RIPK1 2806/4885HDAC11 107/4885HDAC6 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.